180 related articles for article (PubMed ID: 38232438)
1. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.
Infante AF; Elmes AT; Gimbar RP; Messmer SE; Neeb C; Jarrett JB
Int J Drug Policy; 2024 Feb; 124():104323. PubMed ID: 38232438
[TBL] [Abstract][Full Text] [Related]
2. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.
Stolbach AI; Mazer-Amirshahi ME; Nelson LS; Cole JB
Clin Toxicol (Phila); 2023 Nov; 61(11):952-955. PubMed ID: 38039052
[TBL] [Abstract][Full Text] [Related]
3. Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021.
Rock P; Slavova S; Westgate PM; Nakamura A; Walsh SL
Drug Alcohol Depend; 2024 Feb; 255():111062. PubMed ID: 38157702
[TBL] [Abstract][Full Text] [Related]
4. Nalmefene nasal spray (Opvee) for reversal of opioid overdose.
Med Lett Drugs Ther; 2023 Oct; 65(1687):166-167. PubMed ID: 37871116
[No Abstract] [Full Text] [Related]
5. Treatment of opioid overdose: current approaches and recent advances.
Britch SC; Walsh SL
Psychopharmacology (Berl); 2022 Jul; 239(7):2063-2081. PubMed ID: 35385972
[TBL] [Abstract][Full Text] [Related]
6. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
[TBL] [Abstract][Full Text] [Related]
7. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
[TBL] [Abstract][Full Text] [Related]
8. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB
J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307
[TBL] [Abstract][Full Text] [Related]
9. The need for multiple naloxone administrations for opioid overdose reversals: A review of the literature.
Abdelal R; Banerjee AR; Carlberg-Racich S; Darwaza N; Ito D; Epstein J
Subst Abus; 2022; 43(1):774-784. PubMed ID: 35112993
[No Abstract] [Full Text] [Related]
10. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
Wang DS; Sternbach G; Varon J
J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
[TBL] [Abstract][Full Text] [Related]
11. Treatment of overdose in the synthetic opioid era.
Skolnick P
Pharmacol Ther; 2022 May; 233():108019. PubMed ID: 34637841
[TBL] [Abstract][Full Text] [Related]
12. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
Krieter P; Gyaw S; Crystal R; Skolnick P
J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
[TBL] [Abstract][Full Text] [Related]
13. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose.
Krotulski AJ; Chapman BP; Marks SJ; Ontiveros ST; Devin-Holcombe K; Fogarty MF; Trieu H; Logan BK; Merchant RC; Babu KM
Clin Toxicol (Phila); 2022 Feb; 60(2):197-204. PubMed ID: 34278904
[TBL] [Abstract][Full Text] [Related]
14. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
[TBL] [Abstract][Full Text] [Related]
15. Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose.
Disney A; Olson KM; Shafer AM; Moore SC; Anand JP; Traynor JR; Husbands SM
ACS Chem Neurosci; 2022 Nov; 13(21):3108-3117. PubMed ID: 36223082
[TBL] [Abstract][Full Text] [Related]
16. On the front lines of the opioid epidemic: Rescue by naloxone.
Skolnick P
Eur J Pharmacol; 2018 Sep; 835():147-153. PubMed ID: 30092179
[TBL] [Abstract][Full Text] [Related]
17. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest.
van Lemmen M; Florian J; Li Z; van Velzen M; van Dorp E; Niesters M; Sarton E; Olofsen E; van der Schrier R; Strauss DG; Dahan A
Anesthesiology; 2023 Sep; 139(3):342-353. PubMed ID: 37402248
[TBL] [Abstract][Full Text] [Related]
18. Real-world study of multiple naloxone administrations for opioid overdose reversal among emergency medical service providers.
Abdelal R; Banerjee AR; Carlberg-Racich S; Cebollero C; Darwaza N; Kim C; Ito D; Epstein J
Subst Abus; 2022; 43(1):1075-1084. PubMed ID: 35442869
[No Abstract] [Full Text] [Related]
19. The effect of untargeted naloxone distribution on opioid overdose outcomes.
Dowd WN
Health Econ; 2023 Dec; 32(12):2801-2818. PubMed ID: 37670413
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments.
Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R
Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
